Tumor characterization by HRD score testing identifies possible gene mutations (at the level of the BRCA1 and BRCA2 genes in the tumor tissue) and reveals genomic instability through LOH, LST, and TAI (collateral damage). This evidence concerns the gene BRCA2 and neoplasm.